7:02AM Pharmasset: PSI-7977 receives fast track designation from the FDA for the treatment of chronic hepatitis C infection (VRUS) 26.81 : Co has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of chronic hepatitis C. Co recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys plus Copegus in treatment-naive patients chronically infected with chronic hepatitis C genotype 1. Co expects to initiate a 12-week Phase 2b study of PSI-7977 in the fourth quarter of 2010.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.